130 results
D
KPRX
Kiora Pharmaceuticals Inc
14 Feb 24
$15.00 mm in equity / options / securities to be acquired, sold $15.00 mm, 13 investors
3:51pm
that is the subject of this Form D, States cannot
routinely require offering materials under this undertaking or otherwise and can require offering … materials only to the
extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.
8-K
EX-10.1
KPRX
Kiora Pharmaceuticals Inc
1 Feb 24
Kiora Pharmaceuticals Announces Private Placement of up to Approximately $45 Million
7:01am
Materials” shall have the meaning ascribed to such term in Section 3.1(m). “Indebtedness” shall have the meaning ascribed to such term in Section 3.1(aa … as the Company was required by law or regulation to file such materials) (the foregoing materials, including the exhibits thereto and documents incorporated
8-K
EX-10.2
cys2darmr5nk8oabtv2
1 Feb 24
Kiora Pharmaceuticals Announces Private Placement of up to Approximately $45 Million
7:01am
8-K
EX-10.1
znb5lei
31 Jan 24
Entry into a Material Definitive Agreement
5:14pm
DEFA14A
EX-99.1
864wlwgea8h g0o7
1 Sep 23
Additional proxy soliciting materials
7:00am
DEFA14A
naganm jg
1 Sep 23
Additional proxy soliciting materials
7:00am
8-K
EX-99.1
071lmpjvzula5y8hmn2p
1 Sep 23
Kiora Pharmaceuticals Adjourns Special Meeting of Stockholders to September 27
7:00am
8-K
t8vyyte5
1 Sep 23
Kiora Pharmaceuticals Adjourns Special Meeting of Stockholders to September 27
7:00am
8-K
EX-10.2
4zujw jrn72hg5vn4
15 Jun 23
Kiora Pharmaceuticals and Sentrx Animal Care Amend Existing Manufacturing Licensing Agreement for KIO-201
4:59pm
8-K
EX-1.1
4guj 7n610s5ty49d
6 Jun 23
Kiora Pharmaceuticals Announces Pricing of $5.5 Million Underwritten Public Offering
4:52pm
424B1
ftj84n r9j
2 Jun 23
Prospectus with pricing info
5:08pm